Catheterization and Cardiovascular Interventions · 2016 · 124 citations · 11 references
MedicineCardiologyInternal MedicineCell TherapyClinical CardiologyRegenerative MedicineCardiac RegenerationCardiac Tissue EngineeringCoronary Artery DiseaseCoronary Artery SurgeryHeart FailureIschemic Heart DiseaseAdipose Stem CellsCardiac Cell TherapyChronic Ischemic Left Ventricular DysfunctionDouble-blind TrialsLeft Ventricular FailureLeft Ventricular Systolic FunctionMultivessel Coronary Artery DiseaseMyocardial Repair
OBJECTIVE: To assess safety and feasibility of autologous adipose-derived regenerative cells (ADRCs), for treatment of chronic ischemic cardiomyopathy patients. BACKGROUND: Preclinical and early clinical trials suggest ADRCs have excellent potential for ischemic conditions. METHODS: The Athena program consisted of two parallel, prospective, randomized (2:1, active: placebo), double-blind trials assessing intramyocardial (IM) ADRC delivery [40-million, n = 28 (ATHENA) and 80-million (ATHENA II) cells, n = 3]). Patients with an EF ≥20% but ≤45%, multivessel coronary artery disease (CAD) not amenable to revascularization, inducible ischemia, and symptoms of either angina (CCS II-IV) or heart failure (NYHA Class II-III) on maximal medical therapy were enrolled. All patients underwent fat harvest procedure (≤450 mL adipose), on-site cell processing (Celution® System, Cytori Therapeutics), electromechanical mapping, and IM delivery of ADRCs or placebo. RESULTS: max favored ADRCs (+45.4 ± 222 vs. -9.5 ± 137 mL/min) but there was no difference in left ventricular function or volumes. At 12-months, heart failure hospitalizations occurred in 2/17 (11.7%) [ADRC] and 3/14 (21.4%) [placebo]. Differences in NYHA and CCS classes favored ADRCs at 12-months with significant improvement in MLHFQ (-21.6 + 13.9 vs. -5.5 + 23.8, P = 0.038). CONCLUSIONS: A small volume fat harvest, automated local processing, and IM delivery of autologous ADRCs is feasible with suggestion of benefit in "no option" CAD patients. Although the sample size is limited, the findings support feasibility and scalability for treatment of ischemic cardiomyopathy with ADRCs. © 2016 Wiley Periodicals, Inc.
11
Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells
Jalees Rehman, Dmitry O. Traktuev, Jingling Li et al. · Circulation · 2004 · 2.3K citations
Medicine, Cell Biology, Cell Therapy +11
Plasticity of Human Adipose Lineage Cells Toward Endothelial Cells
Valérie Planat‐Benard, Jean‐Sébastien Silvestre, Béatrice Cousin et al. · Circulation · 2004 · 1.4K citations · Full text
Emerson C. Perin, James T. Willerson, Carl J. Pepine et al. · JAMA · 2012 · 455 citations · Full text